BTIG analyst Ryan Zimmerman maintained a Buy rating on Vericel (NASDAQ:VCEL) Corp on Wednesday, setting a price target of $50, which is approximately 21.92% above the present share price of $41.01.
Zimmerman expects Vericel Corp to post earnings per share (EPS) of -$0.11 for the fourth quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Vericel, with an average price target of $56.33.
The analysts price targets range from a high of $65 to a low of $50.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $34.51 million and a net profit of -$4.96 million. The company's market cap is $1.92 billion.
According to TipRanks.com, BTIG analyst Ryan Zimmerman is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 21.9% and a 54.10% success rate.
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.